Delving into the Latest Updates on Lidocaine/Prilocaine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Compound Lidocaine Cream, Emla Cream, Lidocaine/Prilocaine

+ [13]

Target

SCNA x VDCCs

Mechanism

SCNA modulators(Sodium channel alpha subunit modulators), VDCCs modulators(Voltage-gated calcium channel modulators)

Therapeutic Areas

Nervous System DiseasesUrogenital DiseasesOther Diseases

Active Indication

Premature EjaculationPainAnesthesia

Inactive Indication-

Originator Organization

Dentsply Sirona, Inc.

Active Organization

Jiangsu Carephar Pharmaceutical Co., Ltd.Recordati Ireland Ltd.

Pharmaserve (North West) Ltd.

+ [6]

Inactive Organization

Teva Branded Pharmaceutical Products R&D, Inc.Plethora Solutions Ltd.

Drug Highest PhaseApproved

First Approval Date

US (30 Dec 1992),

Anesthesia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC27H42N4O2

InChIKeyWZSPWMATVLBWRS-UHFFFAOYSA-N

CAS Registry101362-25-8

主要目的比较空腹给药条件下，广东泰恩康制药厂有限公司的利丙双卡因乳膏与Aspen Pharmacare Australia Pty Ltd持证的利丙双卡因乳膏（商品名：恩纳/EMLA）在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的评估空腹给药条件下，广东泰恩康制药厂有限公司的利丙双卡因乳膏与Aspen Pharmacare Australia Pty Ltd持证的利丙双卡因乳膏（商品名：恩纳/EMLA）在健康成年人群中的安全性。

[Translation]

Primary objective To compare the differences in the extent and rate of absorption of Guangdong Taienkang Pharmaceutical Co., Ltd.'s levocaine cream and Aspen Pharmacare Australia Pty Ltd's licensed levocaine cream (trade name: EMLA) in healthy adults under fasting conditions and to evaluate their bioequivalence. Secondary objective To evaluate the safety of Guangdong Taienkang Pharmaceutical Co., Ltd.'s levocaine cream and Aspen Pharmacare Australia Pty Ltd's licensed levocaine cream (trade name: EMLA) in healthy adults under fasting conditions.

Start Date02 Dec 2024

Sponsor / Collaborator

Guangdong Taienkang Pharmaceutical Factory Co., Ltd

100 Clinical Results associated with Lidocaine/Prilocaine

Login to view more data

100 Translational Medicine associated with Lidocaine/Prilocaine

Login to view more data

100 Patents (Medical) associated with Lidocaine/Prilocaine

Login to view more data

1,146

Literatures (Medical) associated with Lidocaine/Prilocaine

02 Jan 2025·Physiotherapy Theory and Practice

Comparative effect of triamcinolone/lidocaine ultrasonophoresis and injection on pain, disability, quality of life in patients with acute rotator cuff related shoulder pain: a double blinded randomized controlled trial

Article

Author: Nazary-Moghadam, Salman ; Golmohammadzadeh, Shiva ; Kachoei, Amir Reza ; Zeinalzadeh, Afsaneh ; Moradi, Ali ; Tehrani, Mohammad Reza ; Zare, Mohammad Ali

BACKGROUNDAlleviating inflammation should be considered as one of the first steps of the treatment plan in patients with acute rotator cuff related shoulder pain (RCRSP).OBJECTIVETo compare the effects of triamcinolone/lidocaine ultrasonophoresis, injection on pain, disability, and quality of life in patients with acute RCRSP.METHODSA total of 28 acute RCRSP patients were randomly allocated into two groups of ultrasonophoresis and injection. Both groups received vitamin C and shoulder care education for 10 days and then were subjected to therapeutic interventions. Ultrasonophoresis group received triamcinolone (16 mg) and lidocaine (2mg) using ultrasonophoresis (frequency: 3 MHz, intensity: 1.50 W/Cm2), while the injection group received a single subacromial injection of triamcinolone (80 mg) and lidocaine (10 mg). The main outcomes measures were pain assessed by two scales (visual analog scale), and shoulder pain and disability index (SPADI), disability (SPADI), and quality of life (Western Ontario rotator cuff questionnaire).RESULTSAlthough the main effect of time was statistically significant for all dependent variables (P< 0.01), no significant interaction was found between group and time (P-value (0.12-0.55)). The ultrasonophoresis effect, size for pain, disability, and quality of life were 2.58, 1.43, 1.78, and 1.35, respectively. The injection effect, size for pain, disability, and quality of life were 1.98, 2.02, 1.40, and 1.60, respectively.CONCLUSIONSTriamcinolone/lidocaine ultrasonophoresis demonstrated similar outcomes to injection in reducing pain, improving disability, and enhancing quality of life in patients with acute RCRSP in short time. According to our findings, ultrasonophoresis with triamcinolone/lidocaine cream is as effective as triamcinolone/lidocaine injection and can be proposed as a potential adjunctive treatment for patients with acute RCRSP.

01 Jan 2025·Otolaryngology–Head and Neck Surgery

Topical Anesthesia in Cutaneous Head and Neck Surgery: A Randomized Controlled Trial

Article

Author: McHugh, Nathaniel ; O'Neill, Rory ; Affendi, Adrinda ; Skinner, Liam

AbstractObjectiveCutaneous head and neck surgery can safely and effectively be performed using local anesthetic (LA). However, optimizing pain management during LA administration is paramount for patient comfort and procedural efficacy. The primary objective of this study was to investigate the comparative effectiveness of EMLA cream and ethyl chloride (EC) spray in mitigating pain associated with LA administration in cutaneous head and neck surgery.Study DesignRandomized controlled trial.SettingUniversity‐affiliated tertiary head and neck oncology center.MethodsSample size calculation was performed followed by computer randomization into the following groups: EMLA, EMLA placebo (aqueous cream), EC, and a control group (no topical agent). Demographics, pain, and procedural experience scores were recorded perioperatively. Statistical analysis was performed to analyse differences between groups utilizing the Mann‐Whitney U test, Kruskall‐Wallis test, Chi‐square test, and Spearman's Rho.Results121 cutaneous lesions with a median patient age of 76 were analyzed. There were no statistically significant differences in pain scores (median [IQR]) between patients receiving EMLA (4 [3.75]), EMLA placebo (4.8 [3.6]), EC (5.8 [2.8]), and no treatment (5 [4.1], P = .19). Procedural experience scores were clinically similar (P = .02). Risk factors associated with elevated nociceptive sensitivity were surgical site (scalp, P = .01), malignant lesions (P < .01) and lesion surface area (rs = 0.22, P = .01).ConclusionEMLA and EC did not mitigate LA‐associated pain in patients undergoing cutaneous head and neck surgery and as such practitioners should reconsider their use of these in this regard. Patients' operative experience remains excellent regardless of topical anesthetic use.Level of EvidenceIb.

01 Jan 2025·Pain

Development and validation of a home quantitative sensory testing tool-kit to assess changes in sensory and pain processing: a study in healthy young adults

Article

Author: Lobo, Kimberly ; Ocay, Don Daniel ; Kim, Angela ; Halpin, Meghan ; Berde, Charles B.

AbstractQuantitative sensory testing (QST) is a set of methods for quantifying somatosensory functioning. Limitations of laboratory-based QST (LQST) include high cost, complexity in training, lack of portability, and time requirements for testing. Translating QST to a home setting could facilitate future research and clinical care. The objective of this study was to develop a home QST (HQST) tool-kit that is cost-effective, easy to use, and detects changes in sensory and pain processing. Thirty-two young healthy adults underwent sensory testing on their nondominant forearm using standard in-person LQST, followed by “simulated HQST” using video guidance in a separate room from the investigator before and after application of either a lidocaine or capsaicin cream. We observed good agreement between HQST and LQST scores, with significant correlations observed between the pinprick, pressure, cold and heat measures (|ρ| range = 0.36-0.54). The participants rated the HQST protocol as highly acceptable and safe but can be improved in future implementations. Home QST was able to detect hypoesthesia to vibration after lidocaine cream application (P = 0.024, d = 0.502) and could detect hypoalgesia and hyperalgesia to pressure and heat pain sensitivity tests after application of lidocaine and capsaicin creams, respectively (P-value range = <0.001-0.036, d-value range = 0.563-0.901). Despite limitations, HQST tool-kits may become a cost-effective, convenient, and scalable approach for improving sensory profiling in clinical care and clinical research.

100 Deals associated with Lidocaine/Prilocaine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	N01BB20	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Premature Ejaculation	IS	Recordati Ireland Ltd.	15 Nov 2013
Premature Ejaculation	NO	Recordati Ireland Ltd.	15 Nov 2013
Premature Ejaculation	EU	Recordati Ireland Ltd.	15 Nov 2013
Premature Ejaculation	LI	Recordati Ireland Ltd.	15 Nov 2013
Pain	JP	Sato Pharmaceutical Co., Ltd.	18 Jan 2012
Anesthesia	US	DENTSPLY PHARMACEUTICAL INC	19 Dec 2003

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Premature Ejaculation	Discovery	IS	Plethora Pharma Solutions Ltd.	14 Nov 2019
Premature Ejaculation	Discovery	NO	Plethora Pharma Solutions Ltd.	14 Nov 2019
Premature Ejaculation	Discovery	EU	Plethora Pharma Solutions Ltd.	14 Nov 2019
Premature Ejaculation	Discovery	LI	Plethora Pharma Solutions Ltd.	14 Nov 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04003012 (CTgov)	Phase 4	Pain \| Leukemia \| Lymphoma	10	EMLA (EMLA)	svxmnawahs(moazksxzex) = egqrtuozug zcfhskoiwx (tqrongsrod, lpyglqbbdw - bpatkacnla) View more	-	09 Mar 2023
				Lidocaine (Lidocaine)	rgrwgvtlyx(nhtknbecwx) = eeibiywhmg ijycljhzsk (zrpstyvdal, nujulhlppi - upargyzplc)
NCT04275336 (CTgov)	Not Applicable	Pain	354	EMLA application (EMLA Group)	gyncnehsqs(wnennooqfl) = wcspvzxptk zwearwnsex (pcaegvhtlj, ymnnmrkfkg - ebpfqwpioy) View more	-	06 Oct 2021
				Distraction techniques (Distraction Group)	gyncnehsqs(wnennooqfl) = hvijdfpgfr zwearwnsex (pcaegvhtlj, lqqboopwvs - gomaiydnqr) View more
NCT03654417 (Pubmed \| Obstet Gynecol)	Phase 4	Vulvar Diseases	38	Lidocaine-Prilocaine Cream	isyvetczrd(sgqrvznfox) = wribgacyce nylptlvayn (cyaynbxixm ) View more	-	09 Feb 2020
				Lidocaine Injection	isyvetczrd(sgqrvznfox) = zyziebnvin nylptlvayn (cyaynbxixm ) View more
NCT03654417 (CTgov)	Phase 4	Pain	37	lidocaine (EMLA)	qbegxuotdd(zapoawtyom) = vidijhnurp lfnxafdbwd (ntwfnbtwmf, sfiyojezxy - mviiltyazi) View more	-	18 Jan 2020
				EMLA (Lidocaine)	qbegxuotdd(zapoawtyom) = wgwgdppwyo lfnxafdbwd (ntwfnbtwmf, zpmolxmtcr - wmwtxdypfs) View more
NCT01516684 (CTgov)	Phase 2	Neoplasms	33	EMLA cream (Arm A (EMLA))	skhdqbzdne(viydkqtghj) = ttnlqiotgn fgfoutcwcx (ufjevgovvx, apnrzanahq - jxdtoaqiwo) View more	-	06 Sep 2019
				Placebo (Arm B (Placebo))	skhdqbzdne(viydkqtghj) = bglcgxqkrg fgfoutcwcx (ufjevgovvx, slhisgqywi - gbgnevaett) View more
NCT01628874 (JTIP, CTgov)	Not Applicable	-	66	Placebo+EMLA Cream (EMLA Cream, Then Placebo Via J-Tip)	(duuvmrvqzl) = qrovdglqiu vkwjbdgcfa (bqkvzbittc, fvfffjyjth - ylbzmukcaj) View more	-	21 Jun 2019
				Placebo+Lidocaine (Placebo Cream, Then Lidocaine Via J-Tip)	(duuvmrvqzl) = xgxdfzlmkt vkwjbdgcfa (bqkvzbittc, mvdfykoloh - fwqqwysszc) View more
NCT00530803 (CTgov)	Phase 2	Pain \| Phobic Disorders	100	EMLA Cream (EMLA Cream)	uoohxiglwo(igqudmdzpq) = kkvmuhyqas jfdhwjtlsf (rboppxypia, ytwjykmevk - gqsxpfwjfx) View more	-	31 Aug 2018
				Synera Patch (Synera Patch)	uoohxiglwo(igqudmdzpq) = hqaecskvmh jfdhwjtlsf (rboppxypia, dysxlwqejl - mogwwehsqn) View more
NCT02380742 (CTgov)	Phase 2	Pain	54	lidocaine-prilocaine cream (Lidocaine-prilocaine)	vkhsfolcsd(bnwezacnoa) = xyecgjwypn ssrhhvcsrd (gvagwtxdyv, odaedgrkgl - lqionrkfxx) View more	-	23 Feb 2017
				Placebo cream (Placebo)	vkhsfolcsd(bnwezacnoa) = adbtnerrmi ssrhhvcsrd (gvagwtxdyv, aenldfoqeq - ttnsccabav) View more
1493 PSD 502 (AUA2010)	Phase 3	Premature Ejaculation	256	PSD502	(xsvasgfwew) = ndejlyynxs hktbfojnhm (hrgrjudvlv )	Positive	01 Apr 2010
1494 PSD 502 (AUA2010)	Phase 3	Premature Ejaculation	249	PSD 502	(absfyfgqwn) = jsmxxwziwl pztkvuudje (nsfwnwtzif )	Positive	01 Apr 2010
				Placebo	(absfyfgqwn) = waepeiwwlr pztkvuudje (nsfwnwtzif )